Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients.
As oversedation is still common and significant variability between and within critically ill patients makes empiric dosing difficult, the population pharmacokinetics and pharmacodynamics of propofol upon long-term use are characterized, particularly focused on the varying disease state as determinant of the effect. Twenty-six critically ill patients were evaluated during 0.7-9.5 days (median 1.9 days) using the Ramsay scale and the bispectral index as pharmacodynamic end points. NONMEM V was applied for population pharmacokinetic and pharmacodynamic modeling. Propofol pharmacokinetics was described by a two-compartment model, in which cardiac patients had a 38% lower clearance. Severity of illness, expressed as a Sequential Organ Failure Assessment (SOFA) score, particularly influenced the pharmacodynamics and to a minor degree the pharmacokinetics. Deeper levels of sedation were found with an increasing SOFA score. With severe illness, critically ill patients will need downward titration of propofol. In patients with cardiac failure, the propofol dosages should be reduced by 38%.
Peeters
M Y M
MY
Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands.
Bras
L J
LJ
DeJongh
J
J
Wesselink
R M J
RM
Aarts
L P H J
LP
Danhof
M
M
Knibbe
C A J
CA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016638:Critical Illness / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008956:Models, Chemical; D015742:Propofol / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*; D012720:Severity of Illness Index; D013997:Time Factors
D015742:Propofol